The estimated Net Worth of Joseph J. Sarret is at least $26.8 Mille dollars as of 18 August 2021. Dr Sarret owns over 20,000 units of CohBar Inc stock worth over $8,600 and over the last 14 years he sold CWBR stock worth over $18,240.
Dr has made over 4 trades of the CohBar Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of CWBR stock worth $22,400 on 18 August 2021.
The largest trade he's ever made was buying 20,000 units of CohBar Inc stock on 18 August 2021 worth over $22,400. On average, Dr trades about 2,847 units every 117 days since 2010. As of 18 August 2021 he still owns at least 20,000 units of CohBar Inc stock.
You can see the complete history of Dr Sarret stock trades at the bottom of the page.
Dr. Joseph J. Sarret is the CEO & Director at CohBar Inc.
Dr Sarret is 54, he's been the CEO & Director of CohBar Inc since . There are 11 older and 2 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
Joseph's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy e Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar Inc executives and other stock owners filed with the SEC include: